ANGOAngiodynamics, Inc.Running, no new patients
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Stage III Pancreatic Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Apr 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 528 (planned)
- Started
- Feb 23, 2021
- Main results expected
- Apr 2025
- Fully finished
- Apr 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival
Measured over: Time (in months) from randomization to the date of death for any reason, assessed through at least 24 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-04-01, no fading
Raw record changes
- none yet
Trial ID NCT03899636 · record last updated 2025-02-12 · checked 2026-11-09 15:47 UTC